114 related articles for article (PubMed ID: 23769056)
1. Mouse T cells engineered to display on their surface a novel form of FasL protein undergo apoptosis when stimulated with alloantigens: implications for graft-versus-host disease.
Yolcu ES; Singh NP
Transplant Proc; 2013 Jun; 45(5):1850-2. PubMed ID: 23769056
[TBL] [Abstract][Full Text] [Related]
2. Depletion of naïve lymphocytes with fas ligand ex vivo prevents graft-versus-host disease without impairing T cell support of engraftment or graft-versus-tumor activity.
Askenasy N; Mizrahi K; Ash S; Askenasy EM; Yaniv I; Stein J
Biol Blood Marrow Transplant; 2013 Feb; 19(2):185-95. PubMed ID: 23078782
[TBL] [Abstract][Full Text] [Related]
3. Engineering donor lymphocytes with Fas ligand protein effectively prevents acute graft-versus-host disease.
Shrestha P; Turan A; Batra L; Gulen AE; Sun Z; Tan H; Askenasy N; Shirwan H; Yolcu ES
Blood Adv; 2023 May; 7(10):2181-2195. PubMed ID: 36780582
[TBL] [Abstract][Full Text] [Related]
4. The effect on the proliferation and apoptosis of alloreactive T cells of cell dose in a murine MHC-mismatched hematopoietic cell transplantation model.
Fujioka T; Taniguchi Y; Masuda T; Nishida S; Ikegame K; Kawakami M; Tsuboi A; Hosen N; Murakami M; Oji Y; Oka Y; Sugiyama H; Kawase I; Ogawa H
Transpl Immunol; 2003; 11(2):187-95. PubMed ID: 12799203
[TBL] [Abstract][Full Text] [Related]
5. Ex vivo soluble fas ligand treatment of donor cells to selectively reduce murine acute graft versus host disease.
Georgantas RW; Bohana-Kashtan O; Civin CI
Transplantation; 2006 Aug; 82(4):471-8. PubMed ID: 16926590
[TBL] [Abstract][Full Text] [Related]
6. Activated allogeneic NK cells as suppressors of alloreactive responses.
Hu B; He Y; Wu Y; Bao G; Liu H; Welniak LA; Murphy WJ
Biol Blood Marrow Transplant; 2010 Jun; 16(6):772-81. PubMed ID: 20197103
[TBL] [Abstract][Full Text] [Related]
7. Induction of early post-transplant graft-versus-leukemia effects using intentionally mismatched donor lymphocytes and elimination of alloantigen-primed donor lymphocytes for prevention of graft-versus-host disease.
Yang I; Weiss L; Abdul-Hai A; Kasir J; Reich S; Slavin S
Cancer Res; 2005 Nov; 65(21):9735-40. PubMed ID: 16266994
[TBL] [Abstract][Full Text] [Related]
8. Pancreatic islets engineered with SA-FasL protein establish robust localized tolerance by inducing regulatory T cells in mice.
Yolcu ES; Zhao H; Bandura-Morgan L; Lacelle C; Woodward KB; Askenasy N; Shirwan H
J Immunol; 2011 Dec; 187(11):5901-9. PubMed ID: 22068235
[TBL] [Abstract][Full Text] [Related]
9. Effective graft-versus-leukemia effects independent of graft-versus-host disease after T cell-depleted allogeneic bone marrow transplantation in a murine model of B cell leukemia/lymphoma. Role of cell therapy and recombinant IL-2.
Weiss L; Lubin I; Factorowich I; Lapidot Z; Reich S; Reisner Y; Slavin S
J Immunol; 1994 Sep; 153(6):2562-7. PubMed ID: 8077666
[TBL] [Abstract][Full Text] [Related]
10. Blockade of the CD40/CD154 pathway enhances T-cell-depleted allogeneic bone marrow engraftment under nonmyeloablative and irradiation-free conditioning therapy.
Pan Y; Luo B; Sozen H; Kalscheuer H; Blazar BR; Sutherland DE; Hering BJ; Guo Z
Transplantation; 2003 Jul; 76(1):216-24. PubMed ID: 12865813
[TBL] [Abstract][Full Text] [Related]
11. Facilitation of parental-strain marrow engraftment by T cells of neonatally-tolerant mice.
Davenport C; George T; Devora GA; Morris MA; Gordon BE; Kumar V; Bennett M
Biol Blood Marrow Transplant; 1997 Dec; 3(6):294-303. PubMed ID: 9502296
[TBL] [Abstract][Full Text] [Related]
12. High expression of Fas ligand on cord blood dendritic cells: a possible immunoregulatory mechanism after cord blood transplantation.
Naderi N; Moazzeni SM; Pourfathollah AA; Alimoghaddam K
Transplant Proc; 2011 Dec; 43(10):3913-9. PubMed ID: 22172872
[TBL] [Abstract][Full Text] [Related]
13. Differential expression of Fas and Fas ligand in acute and chronic graft-versus-host disease: up-regulation of Fas and Fas ligand requires CD8+ T cell activation and IFN-gamma production.
Shustov A; Nguyen P; Finkelman F; Elkon KB; Via CS
J Immunol; 1998 Sep; 161(6):2848-55. PubMed ID: 9743345
[TBL] [Abstract][Full Text] [Related]
14. Alloantigen recognition is critical for CD8 T cell-mediated graft anti-tumor activity against murine BCL1 lymphoma after myeloablative bone marrow transplantation.
Pillai A; Teo P; George T; Mukhopadhyay A; Dejbakhsh-Jones S; Strober S
Bone Marrow Transplant; 2007 Sep; 40(5):487-97. PubMed ID: 17603512
[TBL] [Abstract][Full Text] [Related]
15. In vitro-established alloantigen-specific CD8+ CTLs mediate graft-versus-tumor activity in the absence of graft-versus-host disease.
Hartmann N; Leithäuser F; Albers C; Duyster J; Möller P; Debatin KM; Strauss G
Leukemia; 2011 May; 25(5):848-55. PubMed ID: 21331071
[TBL] [Abstract][Full Text] [Related]
16. [Selected elimination of mouse alloreactive T cells by Fas-FasL passway].
Liu L; Zou P; Xu Z; Hu Z; Chen Y; Song S
Zhonghua Xue Ye Xue Za Zhi; 2002 Apr; 23(4):187-90. PubMed ID: 12133454
[TBL] [Abstract][Full Text] [Related]
17. Effect of selective T cell depletion of host and/or donor bone marrow on lymphopoietic repopulation, tolerance, and graft-vs-host disease in mixed allogeneic chimeras (B10 + B10.D2----B10).
Ildstad ST; Wren SM; Bluestone JA; Barbieri SA; Stephany D; Sachs DH
J Immunol; 1986 Jan; 136(1):28-33. PubMed ID: 2933464
[TBL] [Abstract][Full Text] [Related]
18. Posttransplantation systemic immunomodulation with SA-FasL-engineered donor splenocytes has robust efficacy in preventing cardiac allograft rejection in mice.
Zhao H; Woodward KB; Shirwan H; Grimany-Nuno O; Yolcu ES
Transplant Proc; 2013 Jun; 45(5):1805-7. PubMed ID: 23769048
[TBL] [Abstract][Full Text] [Related]
19. Effect of graft-versus-host disease (GVHD) on host hematopoietic progenitor cells is mediated by Fas-Fas ligand interactions but this does not explain the effect of GVHD on donor cells.
Iwasaki T; Hamano T; Saheki K; Kuroiwa T; Kataoka Y; Takemoto Y; Ogata A; Sugihara A; Terada N; Fujimoto J; Kakishita E
Cell Immunol; 1999 Oct; 197(1):30-8. PubMed ID: 10555993
[TBL] [Abstract][Full Text] [Related]
20. FTY720 enhances the activation-induced apoptosis of donor T cells and modulates graft-versus-host disease.
Hashimoto D; Asakura S; Matsuoka K; Sakoda Y; Koyama M; Aoyama K; Tanimoto M; Teshima T
Eur J Immunol; 2007 Jan; 37(1):271-81. PubMed ID: 17154260
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
